Pay in 4 interest-free payments of $6.10 Learn more
Ships within 48 hours Β· Estimated delivery Aug 11 - Aug 16
Cagrilintide is strictly intended for research purposes only and is not approved by the FDA for human use
is an investigator of SUSTech Institute for Biological Electron Microscopy
As oral GLP-1s expand the category, commercial strategy, payer alignment, and operational scale may matter just as much as clinical profiles
WARNING: Not suitable for children under 14, pregnant and lactating women
I recently ansered a question from Flora and I wanted to share it with you: Hi, I would like to have more information about a product before buying it
NHS Access and Eligibility: NICE guidance (TA875, published March 2023) recommends Wegovy only within NHS specialist weight management services (Tier 3/4) for adults with: At least one weight-related comorbidity and a BMI 35 kg/m (or 32.5 kg/m for people from some minority ethnic groups) Treatment limited to a maximum of 2 years However, NHS availability remains extremely limited due to: Restricted commissioning : Many integrated care boards (ICBs) have not yet commissioned Wegovy services Tier 3 weight management requirement : Patients must be managed within specialist NHS weight management programmes Lengthy waiting lists : Where available, waiting times can be substantial and vary by locality Supply constraints : National shortages have further limited NHS prescribing No cost to eligible patients : When accessible, treatment is provided free at the point of care Private Healthcare Access: Private provision offers several advantages: Immediate availability : Consultations often available within days Flexible appointment scheduling : Evening and weekend consultations commonly available Comprehensive support packages : Often more intensive monitoring and multidisciplinary input Significant cost : 100250 per month for medication and consultations
